|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-10-6
|
|
pubmed:abstractText |
The aim of this study was to establish safety and feasibility of oral Rapamycin at two doses-2 mg and 5 mg-in achieving low rates of repeat target lesion revascularization (TLR) in de novo native coronary artery lesions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0735-1097
|
|
pubmed:author |
pubmed-author:AbbottMaureen CMC,
pubmed-author:AjaniAndrew EAE,
pubmed-author:CanosDanielD,
pubmed-author:GamboneLouiseL,
pubmed-author:KentKenneth MKM,
pubmed-author:KuchulakantiPramodP,
pubmed-author:LindsayJosephJ,
pubmed-author:Oral Rapamune to Inhibit Restenosis study,
pubmed-author:PappasChrysoulaC,
pubmed-author:PichardAugusto DAD,
pubmed-author:PinnowEllenE,
pubmed-author:SatlerLowell FLF,
pubmed-author:TorgusonRebeccaR,
pubmed-author:WaksmanRonR,
pubmed-author:WeissmanNeilN
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1386-92
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15464317-Administration, Oral,
pubmed-meshheading:15464317-Aged,
pubmed-meshheading:15464317-Coronary Angiography,
pubmed-meshheading:15464317-Coronary Artery Disease,
pubmed-meshheading:15464317-Coronary Restenosis,
pubmed-meshheading:15464317-Drug Administration Schedule,
pubmed-meshheading:15464317-Female,
pubmed-meshheading:15464317-Follow-Up Studies,
pubmed-meshheading:15464317-Humans,
pubmed-meshheading:15464317-Male,
pubmed-meshheading:15464317-Middle Aged,
pubmed-meshheading:15464317-Sirolimus,
pubmed-meshheading:15464317-Stents,
pubmed-meshheading:15464317-Treatment Outcome,
pubmed-meshheading:15464317-Ultrasonography, Interventional
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
|
|
pubmed:affiliation |
Cardiovascular Research Institute, Washington Hospital Center, Washington, DC, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
